DR. STEPHEN PAUL REIBEL MD
Prescription History 1508943739
Psychiatry & Neurology - Psychiatry in Ny, NY

NPI Status: Active since November 01, 2006

Contact Information

150 E 93RD ST
NY, NY
ZIP 10128
Phone: (212) 369-3990

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. STEPHEN PAUL REIBEL MD, an active Psychiatry specialist practicing in Ny, NY. Our medical registry currently tracks 4 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 115 documented patient claims. Among these therapy options, the most frequently utilized medication is Clonazepam, which accounts for 46 claims alone.

Medication Index

No matching medications currently found on file.

Alprazolam

Generic Formulation: AlprazolamSpecialty: Psychiatry
Provider Metrics Summary
Total Claims 26
30-Day Fills 26.0
Days Supply 780
NY State Average Benchmarks
Peer Average Claims54.0
Peer Average 30-Day Fills56.3
Peer Average Days Supply1,525
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 51.9% less volume than the regional standard for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $235.41 across this reporting matrix range.

Provider Avg Cost Per Claim

$9.05

State Avg Cost Per Claim

$10.85

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A triazolobenzodiazepine compound with antianxiety and sedative-hypnotic actions, that is efficacious in the treatment of PANIC DISORDERS, with or without AGORAPHOBIA, and in generalized ANXIETY DISORDERS. (From AMA Drug Evaluations Annual, 1994, p238)

Therapeutic Applications

Alprazolam is used to treat anxiety and panic disorders. It belongs to a class of medications called benzodiazepines which act on the brain and nerves (central nervous system) to produce a calming effect. It works by enhancing the effects of a certain natural chemical in the body (GABA).

Bupropion Xl

Generic Formulation: Bupropion HclSpecialty: Psychiatry
Provider Metrics Summary
Total Claims 29
30-Day Fills 77.0
Days Supply 2,290
NY State Average Benchmarks
Peer Average Claims39.0
Peer Average 30-Day Fills65.2
Peer Average Days Supply1,933
Conservative Utilization

This provider writes prescriptions for this formulation 25.6% less frequently than the standard regional baseline metric for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $764.99 across this reporting matrix range.

Provider Avg Cost Per Claim

$26.38

State Avg Cost Per Claim

$38.14

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Bupropion is used to treat depression. It can improve your mood and feelings of well-being. It may work by helping to restore the balance of certain natural chemicals (neurotransmitters) in your brain.

Clonazepam

Generic Formulation: ClonazepamSpecialty: Psychiatry
Provider Metrics Summary
Total Claims 46
30-Day Fills 46.0
Days Supply 1,380
NY State Average Benchmarks
Peer Average Claims51.0
Peer Average 30-Day Fills53.3
Peer Average Days Supply1,511
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $395.30 across this reporting matrix range.

Provider Avg Cost Per Claim

$8.59

State Avg Cost Per Claim

$10.30

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An anticonvulsant used for several types of seizures, including myotonic or atonic seizures, photosensitive epilepsy, and absence seizures, although tolerance may develop. It is seldom effective in generalized tonic-clonic or partial seizures. The mechanism of action appears to involve the enhancement of GAMMA-AMINOBUTYRIC ACID receptor responses.

Therapeutic Applications

Clonazepam is used to prevent and control seizures. This medication is known as an anticonvulsant or antiepileptic drug. It is also used to treat panic attacks. Clonazepam works by calming your brain and nerves. It belongs to a class of drugs called benzodiazepines.

Mirtazapine

Generic Formulation: MirtazapineSpecialty: Psychiatry
Provider Metrics Summary
Total Claims 14
30-Day Fills 34.0
Days Supply 1,020
NY State Average Benchmarks
Peer Average Claims54.0
Peer Average 30-Day Fills69.7
Peer Average Days Supply1,938
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 74.1% less volume than the regional standard for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $332.47 across this reporting matrix range.

Provider Avg Cost Per Claim

$23.75

State Avg Cost Per Claim

$20.97

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A piperazinoazepine tetracyclic compound that enhances the release of NOREPINEPHRINE and SEROTONIN through blockage of presynaptic ALPHA-2 ADRENERGIC RECEPTORS. It also blocks both 5-HT2 and 5-HT3 serotonin receptors and is a potent HISTAMINE H1 RECEPTOR antagonist. It is used for the treatment of depression, and may also be useful for the treatment of anxiety disorders.

Therapeutic Applications

Mirtazapine is used to treat depression. It improves mood and feelings of well-being. Mirtazapine is an antidepressant that works by restoring the balance of natural chemicals (neurotransmitters) in the brain.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. STEPHEN PAUL REIBEL MD provides transparency into local medical care patterns within Ny, NY.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Psychiatry** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.